Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
- 8 April 2014
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 73 (6) , 1197-1204
Abstract
Bevacizumab treatment is associated with tumor shrinkage and hearing improvement in about 50 % of neurofibromatosis 2 (NF2) patients with progressive vestibular schwannomas. Hypertension and proteinuria are common side effects of treatment. However, the long-term toxicity of bevacizumab in this population has not been reported. We reviewed the medical records of all NF2 patients treated with compassionate care bevacizumab at our institution. Hypertension was defined as a systolic blood pressure ≥140 or a diastolic blood pressure ≥90. Proteinuria was measured by urine dipstick. Time-to-event analyses were conducted for hypertension and proteinuria. The relationship of cumulative dose of bevacizumab to mean arterial pressure (MAP) was examined using mixed model analysis, while the relationship to urine protein was examined using generalized estimating equations. Thirty-three patients (median age 28 years) were included in the study, with a median treatment time of 34.1 months. 15/26 (58 %) patients became hypertensive and 18/29 (62 %) developed proteinuria during treatment. Median time to develop hypertension was 12.8 months. Median time to develop 1+ and 2+ proteinuria was 23.7 and 31.9 months, respectively. Eight patients required treatment holidays for proteinuria (median length 3.2 months). A significant positive relationship existed between cumulative bevacizumab dose and MAP (p < 0.0001) but not between cumulative dose and proteinuria (p > 0.30). In our cohort of NF2 patients, extended use of bevacizumab was associated with manageable toxicity. However, bevacizumab treatment still requires careful monitoring of blood pressure and proteinuria, and future studies should investigate optimal dosing schedules to minimize long-term toxicity.Keywords
This publication has 22 references indexed in Scilit:
- Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III StudiesThe Oncologist, 2013
- Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertensionAnnals of Oncology, 2012
- Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2Otology & Neurotology, 2012
- Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapyThe Journal of Laryngology & Otology, 2011
- Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular SystemCirculation, 2011
- Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a BiomarkerSeminars in Nephrology, 2010
- Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2Neuro-Oncology, 2009
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2New England Journal of Medicine, 2009
- Neurofibromatosis type 2Journal of Medical Genetics, 2000
- Neurofibromatosis 1 (Recklinghausen Disease) and Neurofibromatosis 2 (Bilateral Acoustic Neurofibromatosis)Annals of Internal Medicine, 1990